Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

$3.7m for Advanance's "direct detection" molecular Dx tech:

This article was originally published in Clinica

Executive Summary

Canadian start-up Adnavance Technologies is pushing ahead with development of its metallised-DNA (M-DNA) technology using the $3.7m it raised in a series B financing. The round was led by the Working Opportunity Fund, which is managed by GrowthWorks Capital, JovInvestment Management and Business Development Bank of Canada. Vancouver, British Columbia-based Adnavance is developing a direct detection molecular diagnostic technology, which eliminates the need for amplification of the DNA/RNA in the patient's sample. This allows hospitals and smaller independent labs to conduct their own testing, said Adnavance. The company will initially develop an M-DNA test for MRSA, which is expected to hit the market in 2010. In conjunction with the financing, Adnavance also announced the appointment of Randy White as CEO. Dr White's molecular diagnostics experience includes serving as CEO for Xenomics and Nanogen.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel